Search reports, ask a question, or jump to a page.
The problem
Intervention: Somapacitan (once-weekly growth hormone) compared with daily growth hormone injections
Who it was tested with: Children with growth hormone deficiency enrolled in REAL 3, REAL 4, and REAL 6 randomised trials.
Children or communities are compared with a group that did not receive the intervention, or followed over years. This is the design that best separates what the intervention did from everything else that changed.
"Participants receiving somapacitan 0.16 mg/kg/week or daily GH 0.034 mg/kg/day were included. Some participants switched from daily GH to somapacitan after 52 weeks of treatment, so data beyond week 52 were analysed separately." This demonstrates a randomised trial design with a crossover component, providing experimental evidence that both treatment regimens are equivalent in efficacy and safety.
The analysis combines data from multiple trials across different time periods; some participants switched treatments at week 52, making long-term comparisons between groups more complex. Specific adverse event rates and types are not detailed in the abstract.
Across countries and designs
1 study · 0 countries
Not yet reviewed by a person. Model output is not AICS's view until reviewed.
claude-haiku-4-5-20251001 · synth-v1
